Infinata Report

Template ID : 2705 Edit

Access More Information on Albemarle Corporation !

	Corporate Tracker Subscribers have complete access to all available research and information on Albemarle Corporation including detailed executive and manager listings, financial data, M&A and financing activities, personnel changes and more. Register for a free trial today and see what you've been missing.

330 South Fourth Street

Richmond, VA 23210

USA

Phone

804.788.6000

Company Information

Company Information
Industry	Chemicals and Related Industries

# of Employees	3560

Ownership	Public Company

SIC Code	2821

Company Security Requirements	1. Very High

Company Storage Requirements	1. Very High

Fortune 1000 Rank	774

Description

Albemarle Corporation is a developer, manufacturer and marketer of specialty chemicals. The Company sells a diversified mix of products to customers, including manufacturers of electronics, building and construction materials, automotive parts, packaging, pharmachemicals and agrichemicals, as well as to petroleum refiners. Its operations are managed and reported as three operating segments: Polymer Additives, Catalysts and Fine Chemicals. The Polymer Additives segment consists of two product categories: flame retardants, and stabilizers and additives. The Catalysts segment includes refinery catalysts and polyolefin catalysts. The Fine Chemicals segment consists of four product categories: performance chemicals, pharmachemicals, agrichemicals, and fine chemistry services and intermediates (FCSI).

Top Executives

Executive Name	Title
Allen, William	Chief Financial Officer, Catalysts Segment
Diemer, Richard	Chief Financial Officer, Senior Vice President
Labauve, Donald	Chief Financial Officer, Fine Chemicals Segment
Newbill, George	Executive Vice President - Manufacturing Operations
Rohr, Mark	President, Chief Executive Officer, Director
Steitz, John	Chief Operating Officer, Executive Vice President

View All Albemarle Corporation Management and Contacts Available thru Corporate Tracker

Corporate Tracker doesn't just provide C-level executives, but goes deep within the organizational structure of the companies, governments and academic institutions that we track. This ensures that you are able to identify the decision makers and influencers that allow you to grow your business.

Register for a free trial today and view all executives and managers.

Recent Company Events

Date	Type of Event	Details
2008-02-27	Earnings/Dividends	The Board of Directors of Albemarle Corporation today increased the quarterly dividend to $0.12 per share. The dividend is payable April 1, 2008 to shareholders of record at the close of business as of March 15, 2008. The annualized dividend rate is 48 cents per share. (Logo: http://www.newscom.com/cgi bin/prnh/20050801/ALBEMARLELOGO ) "This 14 percent dividend increase is a reflection of the strong financial performance of the company and represents the 14th consecutive year of annual dividend increases," stated Mark Rohr, President and Chief Executive Officer of Albemarle. "We are proud of our long history of dividend growth and expect future performance to allow this trend to continue." Albemarle Corporation, headquartered in Richmond, Virginia, is a leading global developer, manufacturer and marketer of highly engineered specialty chemicals for consumer electronics; petroleum and petrochemical processing; transportation and industrial products; pharmaceuticals; agricultural products; and construction and packaging materials. The Company operates in three business segments Polymer Additives, Catalysts and Fine Chemicals, and serves customers in approximately 100 countries. Learn more about Albemarle at http://www.albemarle.com. "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding Albemarle Corporation's business which are not historical facts are "forward looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward looking statements, see "Risk Factors" in the Company's Annual Report on Form 10 K. s.server=server() s.channel="news release" s.pageName="news_release_dividend increase announced by albemarle" s.prop2="109" s.prop3="02 27 2008" /*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code); //
2008-01-31	Alliances	Anthera Pharmaceuticals, Inc. today announced it has entered into manufacturing agreements with Albemarle Corporation and Patheon Inc. The agreements provide for the large-scale clinical production of Varespladib (A-002), which is expected to be necessary in preparation for Anthera's Phase III clinical trials and planned New Drug Application submission to the Food and Drug Administration. Varespladib is Anthera's oral drug candidate for the treatment of cardiovascular disease. Building on the work done by Anthera's licensor, Eli Lilly, Albemarle will be responsible for process optimization and manufacture of cGMP quantities of the API. Patheon will be responsible for finished tablet production. The agreement also provides an option for the commercial production of Varespladib in the future. Financial terms were not disclosed. "These agreements with Albemarle and Patheon provide Anthera with key supply chain resources for the manufacture of Varespladib," said Paul F. Truex, President and Chief Executive Officer of Anthera Pharmaceuticals. "We are pleased to have secured outstanding technical organizations with significant commercial expertise that will contribute to the future success of the Varespladib program." "We're delighted that Anthera has selected Albemarle as its API manufacturing supplier for its next phase of development," said David Clary, Albemarle Division Vice President of Fine Chemistry Services. "Our relationship with Anthera further demonstrates our proven abilities to support the chemistry and cGMP needs of emerging pharmaceutical companies." "This agreement with Anthera illustrates our continued progress towards becoming the development and manufacturing partner of choice to global pharmaceutical and biotechnology companies," said Dr. Shabbir Anik, Patheon's President of Global Pharmaceutical Development Services. "We look forward to continuing to work with Anthera on the dosage form development and commercial scale up of Varespladib."
2008-01-31	Contract/Agreements	Fine Chemistry Services unit to scale up manufacturing in preparation for Phase III trial of Varespladib BATON ROUGE, La., Jan. 31 /PRNewswire FirstCall/ Albemarle Corporation , a leading global provider of custom pharmaceutical manufacturing services, has entered into a manufacturing agreement with Anthera Pharmaceuticals in preparation for the Phase III clinical trial of Varespladib (A 002), a potential new, oral anti inflammatory drug aimed at treating preconditions that can lead to heart disease. (Logo: http://www.newscom.com/cgi bin/prnh/20050801/ALBEMARLELOGO ) Building on the work done by Anthera's licensor, Eli Lilly, Albemarle will be responsible for process optimization and manufacture of cGMP quantities of the active pharmaceutical ingredient (API). The agreement also provides an option for the commercial production of Varespladib in the future. Varespladib is aimed at helping patients who use "statin therapies" reduce harmful cholesterol levels and inflammation, two factors that can lead to hardening of the arteries. Anthera recently reported results of small scale (or Phase II) studies of Varespladib and their plans to scale up production for the Phase III trial, a large scale, pre commercial research study of drug safety and effectiveness. In October 2007, Anthera reported that the first Phase II trial revealed that "A 002 treatment resulted in significant positive changes on lipoproteins and inflammation," major factors believed to lead to narrowing or hardening of the arteries among cardiovascular patients treated with statins. Earlier in January 2008, Anthera reported preliminary results of a second Phase IIb clinical trial of Varespladib, in which "administration of once daily A 002 lowered both lipoproteins and inflammation levels, confirming the positive effects of A 002 treatment seen in an earlier twice daily study announced in October 2007." As part of the manufacturing agreement, Albemarle's Fine Chemistry Services (FCS) scientists at the company's South Haven, Michigan facility will conduct additional research on the chemical synthesis of Varespladib and fine tune the production process to make a larger scale quantity of the drug in preparation for Phase III clinical trials. "The Albemarle FCS group was selected as our primary API supplier because of their technical skill set, and their expertise in the chemical development of small molecule APIs and cGMP manufacturing," said Debra Odink, Ph.D., Vice President of Pharmaceutical Research and Development at Anthera Pharmaceuticals. "We are very pleased that they will be working with us on the Varespladib program." "We are delighted that Anthera has selected Albemarle FCS to manufacture this important compound," said David Clary, Albemarle Division Vice President of Fine Chemistry Services. "Our ability to support our customers' needs from pre clinical trials into commercialization has resulted in a positive response from the pharmaceutical industry, as evidenced by the steady growth in our chemistry services business. Anthera's selection underlines our proven abilities to support the chemistry needs of developing pharmaceutical companies." California based Anthera Pharmaceuticals is a privately held company that develops and commercializes clinical products to address the unmet medical needs of patients with life threatening chronic and acute inflammatory diseases. For more information please visit http://www.anthera.com. Albemarle Corporation, headquartered in Richmond, Virginia, is a leading global developer, manufacturer and marketer of highly engineered specialty chemicals for consumer electronics; petroleum and petrochemical processing; transportation and industrial products; pharmaceuticals; agricultural products; and construction and packaging materials. The Company operates in three business segments Polymer Additives, Catalysts and Fine Chemicals, and serves customers in approximately 1
2008-01-28	Earnings/Dividends	Full year and fourth quarter highlights: Record annual net income of $230 million Record annual operating profit of $310 million Record annual Catalyst sales and segment income of $894 million and $155 million, up 6.6% and 25.2%, respectively Fourth quarter fully diluted earnings per share (EPS) of $0.60/share Fourth quarter net sales increased 2.5% year over year and 2.6% sequentially Fourth quarter operating profit up 0.9% year over year Three Months Year Ended December 31, Ended December 31, In thousands, except per share amounts 2007 2006 2007 2006 Net Sales $599,156 $584,537 $2,336,187 $2,368,506 Operating Profit $77,500 $76,841 $309,887 $177,484 Net Income $58,620 $62,977 $229,690 $142,969 Diluted EPS $0.60 $0.65 $2.36 $1.47 Albemarle Corporation (NYSE: ALB) reported fourth quarter 2007 net income of $58.6 million, or 60 cents per share, down from $63.0 million, or 65 cents per share, for the fourth quarter of 2006. This decline was principally due to tax benefits recorded in 2006 for changes in foreign statutory tax rates. Operating profit increased to $77.5 million as record performance in the Company's Catalysts business segment and corporate cost reductions were partially offset by declines in the Polymer Additives and Fine Chemicals business segments. The Company reported net sales in the fourth quarter of 2007 totaling $599 million compared to fourth quarter 2006 net sales of $585 million. (Logo: http://www.newscom.com/cgi bin/prnh/20050801/ALBEMARLELOGO ) Net income for 2007 was $229.7 million, or $2.36 per share, up 61 percent from $143.0 million, or $1.47 per share, for 2006. Excluding the second quarter charge related to the closure of our Dayton fine chemistry facility, net income for 2007 was $232.9 million, or $2.40 per share. Net income for 2006, excluding the third quarter charge related to the divestiture of the Thann, France facility, was $201.4 million, or $2.07 per share. Net sales for 2007 were $2.34 billion compared to $2.37 billion for 2006. Commenting on results, Mark C. Rohr, President and CEO, stated, "We ended 2007 with solid results in a tough economic environment. Achieving record annual earnings, 16 percent above 2006 excluding the Thann and Dayton charges, demonstrates the value of our strategy to drive earnings growth and value for our shareholders. All three business segments executed well in the face of raw material inflation and soft demand in some of our consumer related products. Our diverse portfolio, geographic balance, and commitment to operational excellence position us to achieve solid earnings growth in 2008." Quarterly Segment Results Fine Chemicals net sales for the fourth quarter of 2007 were $131.1 million, a 20 percent decrease versus the fourth quarter of 2006. This decline is due primarily to reduced revenue from clear brines volumes and the absence of TAMIFLU(R) intermediates sales that positively impacted fourth quarter 2006 revenue. Segment income for the fourth quarter of 2007 decreased 22 percent versus the fourth quarter of 2006 to $17.7 million due to reduced volume and higher costs in Performance Chemicals partially offset by improved pricing and costs in Fine Chemistry Services. Fine Chemicals full year segment income of $86.9 million improved 40 percent over 2006. Polymer Additives recorded net sales for fourth quarter 2007 of $233.6 million, a 2 percent increase versus the fourth quarter of 2006. Net sales increased in our stabilizers and curatives portfolio due primarily to improved pricing. Flame retardants net sales declined year over year primarily due to reduced volumes in brominated flame retardants, partially offset by improvements in mineral flame retardants sales, pricing and product mix. Polymer Additives segment income for the fourth quarter of 2007 declined 21 percent from the fourth quarter of 2006 to $30.3 million due primarily to lower br

For assistance call Corporate Tracker Support at 1.866.501.6948

--------------------------------------------------------------------- --------------------------------------------------------------------- --------------------------------------------------------------------- ---------------------------------------------------------------------